Nanotechnology of the life sciences: 6 Nanomaterials for cancer therapy
Gespeichert in:
| Weitere Verfasser: | |
|---|---|
| Format: | Buch |
| Sprache: | English |
| Veröffentlicht: |
Weinheim
Wiley-VCH-Verl.
2011
|
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | XIX, 413 S. Ill., graph. Darst. |
| ISBN: | 9783527331369 |
Internformat
MARC
| LEADER | 00000nam a2200000 cc4500 | ||
|---|---|---|---|
| 001 | BV039691964 | ||
| 003 | DE-604 | ||
| 005 | 20230825 | ||
| 007 | t | ||
| 008 | 111109s2011 gw ad|| |||| 00||| eng d | ||
| 015 | |a 11,A38 |2 dnb | ||
| 016 | 7 | |a 1014987741 |2 DE-101 | |
| 020 | |a 9783527331369 |9 978-3-527-33136-9 | ||
| 035 | |a (OCoLC)918160013 | ||
| 035 | |a (DE-599)DNB1014987741 | ||
| 040 | |a DE-604 |b ger |e rakddb | ||
| 041 | 0 | |a eng | |
| 044 | |a gw |c XA-DE-BW | ||
| 049 | |a DE-634 | ||
| 084 | |a 620 |2 sdnb | ||
| 084 | |a 610 |2 sdnb | ||
| 245 | 1 | 0 | |a Nanotechnology of the life sciences |n 6 |p Nanomaterials for cancer therapy |c ed. by Challa S. S. R. Kumar |
| 264 | 1 | |a Weinheim |b Wiley-VCH-Verl. |c 2011 | |
| 300 | |a XIX, 413 S. |b Ill., graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 700 | 1 | |a Kumar, Challa S. S. R. |0 (DE-588)129740470 |4 edt | |
| 773 | 0 | 8 | |w (DE-604)BV039691867 |g 6 |
| 856 | 4 | 2 | |m DNB Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=024540714&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 943 | 1 | |a oai:aleph.bib-bvb.de:BVB01-024540714 | |
Datensatz im Suchindex
| _version_ | 1805145525546123264 |
|---|---|
| adam_text |
IMAGE 1
CONTENTS
PREFACE XIII
LIST OF CONTRIBUTORS XVII
1 CONVENTIONAL CHEMOTHERAPEUTIC DRUG NANOPARTICLES FOR CANCER TREATMENT
1 LOREDANA SERPE 1.1 INTRODUCTION 1
1.2 CANCER AS DRUG DELIVERY TARGET 2 1.3 NANOPARTICLES AS ANTICANCER
DRUG DELIVERY SYSTEM 4 1.3.1 CONVENTIONAL NANOPARTICLES 5 1.3.2
STERICALLY STABILIZED NANOPARTICLES 6 1.3.3 ACTIVELY TARGETABLE
NANOPARTICLES 8 1.3.4 ROUTES OF DRUG NANOPARTICLES ADMINISTRATION 10 1.4
ANTICANCER DRUG NANOPARTICLES 12 1.4.1 ANTHRACYCLINES 12 1.4.1.1 REVERSE
OF P-GLYCOPROTEIN MEDIATED MULTIDRUG RESISTANCE OF CANCER CELLS
TO DOXORUBICIN 17 1.4.2 ANTIESTROGENS 19 1.4.3 ANTI-METABOLITES 20 1.4.4
CAMPTOTHERINS 20 1.4.5 CISPLATIN 21
1.4.6 PADITAXEL 21
1.4.7 MISCELLANEOUS AGENTS 26 1.4.7.1 ARSENIC TRIOXIDE 26 1.4.7.2
BUTYRIC ACID 26 1.4.7.3 CYSTATINS 26 1.4.7.4
DIETHYLENETRIAMINEPENTAACETIC ACID 26 1.4.7.5 MITOXANTRONE 27 1.4.8 GENE
THERAPY 27
REFERENCES 30
BIBLIOGRAFISCHE INFORMATIONEN HTTP://D-NB.INFO/1014987741
DIGITALISIERT DURCH
IMAGE 2
VI CONTENTS
2 NANOPARTICLES FOR PHOTODYNAMIC THERAPY OF CANCER 40
MAGALI ZEKSER-LABOUEBE, ANGELICA VARGAS, AND FLORENCE DELIE
2.1 INTRODUCTION 40
2.2 CONCEPT AND BASIS OF PHOTODYNAMIC THERAPY AND PHOTODETECTION 41
2.2.1 MECHANISMS OF PHOTODYNAMIC THERAPY AND PHOTODIAGNOSIS 41 2.2.2
SELECTIVE TUMOR UPTAKE OF PHOTOSENSITIZERS 43
2.2.3 PHOTOSENSITIZERS 45 2.2.3.1 CONVENTIONAL PHOTOSENSITIZERS 45
2.2.3.2 NEW ENTITIES 47 2.2.4 PHOTODYNAMIC THERAPY: ADVANTAGES AND
LIMITATIONS 51 2.2.5 PHOTOSENSITIZER FORMULATIONS 53
2.3 NON-BIODEGRADABLE NANOPARTICLES FOR PHOTODYNAMIC THERAPY 54 2.3.1
METALLIC NANOPARTICLES 54 2.3.2 CERAMIC NANOPARTICLES 55 2.3.3
NANOPARTICLES MADE OF NON-BIODEGRADABLE POLYMERS 56
2.4 BIODEGRADABLE POLYMERIC NANOPARTICLES FOR PHOTODYNAMIC THERAPY 57 2
A.I PREPARATION OF BIODEGRADABLE POLYMERIC NANOPARTICLES 58 2.4.1.1 IN
SITU POLYMERIZATION 58 2.4.1.2 DISPERSION OF A PREFORMED POLYMER 59
2.4.1.3 "STEALTH" PARTICLES 60 2.4.1.4 TARGETED NANOPARTICLES 60 2.4.2
IN VITRO RELEVANCE OF POLYMERIC NANOPARTICLES IN PDT ON CELL MODELS 62
2.4.2.1 PHOTODYNAMIC ACTIVITY OF PS-LOADED NANOPARTICLES 62 2.4.2.2
UPTAKE AND TRAFFICKING OF PHOTOSENSITIZERS 66
2.4.3 IN VIVO RELEVANCE OF POLYMERIC NANOPARTICLES IN PDT 70 2.4.3.1
BIODISTRIBUTION AND PHARMACOKINETICS OF PHOTOSENSITIZERS COUPLED TO
NANOPARTICLES 70 2.4.3.2 VASCULAR EFFECTS 71 2.4.3.3 IN VIVO EFFICACY ON
TUMOR TUMOR SUPPRESSION EFFECTS 73
2.4.3.4 ADVERSE EFFECTS 74 2.5 CONCLUSIONS 75
ACKNOWLEDGMENTS 75 ABBREVIATIONS 76 REFERENCES 77
3 NANOPARTICLES FOR NEUTRON CAPTURE THERAPY OF CANCER 87 HIDEKI
ICHIKAWA, HIROYUKI TOKUMITSU, MASAHITO MIYAMOTO, AND YOSHINOBU
FUKUMORI
3.1 INTRODUCTION 87
3.2 PRINCIPLE OF NEUTRON CAPTURE THERAPY OF CANCER 88 3.3 BORON NEUTRON
CAPTURE THERAPY 89 3.3.1 BORON COMPOUNDS 89 3.3.2 DELIVERY OF BORON
USING NANOPARTICLES 90 3.4 APPROACHES TO GDNCT 93
IMAGE 3
CONTENTS VII
3.4.1 TYPICAL RESEARCH ON GDNCT 94
3.4.2 DELIVERY OF GADOLINIUM USING LIPID EMULSION (GD-NANOLE) 95 3.4.2.1
PREPARATION OF GD-NANOLE 95 3.4.2.2 BIODISTRIBUTION OF GADOLINIUM AFTER
INTRAPERITONEAL ADMINISTRATION OF GD-NANOLE 98
3.4.2.3 BIODISTRIBUTION OF GADOLINIUM AFTER INTRAVENOUS ADMINISTRATION
OF GD-NANOLE 102 3.4.3 DELIVERY OF GADOLINIUM USING CHITOSAN
NANOPARTICLES (GD- NANOCPS) 204 3.4.3.1 PREPARATION OF GD-NANOCPS 205
3.4.3.2 GD-DTPA RELEASE PROPERTY OF GD-NANOCPS 107
3.4.3.3 GD-DTPA RETENTION IN TUMOR TISSUE AFTER INTRATUMORAL INJECTION
207 3.4.3.4 IN VIVO GROWTH SUPPRESSION OF EXPERIMENTAL MELANOMA SOLID
TUMOR 108 3.4.3.5 BIOADHESION AND UPTAKE OF GD-NANOCP IN THREE DIFFERENT
CELL
LINES 209
3.5 CONCLUSIONS 213
REFERENCES 114
4 NANOVEHICLES AND HIGH MOLECULAR WEIGHT DELIVERY AGENTS FOR BORON
NEUTRON CAPTURE THERAPY 122
CONG WU, ROLFF. BARTH, WEILIAN YANG, ROBERT LEE, WERNER TJARKS,
MARINA V. BACKER, AND JOSEPH M. BACKER
4.1 INTRODUCTION 122
4.1.1 OVERVIEW 122 4.1.2 GENERAL BACKGROUND 123 4.2 GENERAL REQUIREMENTS
FOR BORON DELIVERY AGENTS 124 4.3 LOW MOLECULAR WEIGHT DELIVERY AGENTS
124 4.4 HIGH MOLECULAR WEIGHT BORON DELIVERY AGENTS 125 4.5
DENDRIMER-RELATED DELIVERY AGENTS 125 4.5.1 PROPERTIES OF DENDRIMERS 225
4.5.2 BORONATED DENDRIMERS LINKED TO MONOCLONAL ANTIBODIES 226 4.5.2.1
BORON CLUSTERS DIRECTLY LINKED TO MAB 226 4.5.2.2 ATTACHMENT OF
BORONATED DENDRIMERS TO MAB 129 4.5.3 BORONATED DENDRIMERS DELIVERED BY
RECEPTOR LIGANDS 127 4.5.3.1 EPIDERMAL GROWTH FACTORS (EGF) 227 4.5.3.2
FOLATE RECEPTOR TARGETING AGENTS 229 4.5.3.3 VASCULAR ENDOTHELIAL GROWTH
FACTOR (VEGF) 129 4.5.4 OTHER BORONATED DENDRIMERS 230 4.6 LIPOSOMES AS
BORON DELIVERY AGENTS 230 4.6.1 OVERVIEW OF LIPOSOMES 130 4.6.2
LIPOSOMAL ENCAPSULATION OF SODIUM BOROCAPTATE AND
BORONOPHENYLALANINE 233 4.6.2.1 BORON DELIVERY BY NON-TARGETED LIPOSOMES
233 4.6.2.2 LIPOSOMAL ENCAPSULATION OF OTHER BORANES AND CARBORANES 134
IMAGE 4
VIII CONTENTS
4.6.3 BORON DELIVERY BY TARGETED LIPOSOMES 237
4.6.3.1 IMMUNOLIPOSOMES 237 4.6.3.2 FOLATE RECEPTOR-TARGETED LIPOSOMES
138 4.6.3.3 EGFR TARGETED LIPOSOMES 138 4.7 BORON DELIVERY BY DEXTRANS
139
4.8 OTHER MACROMOLECULES USED FOR DELIVERING BORON COMPOUNDS 142 4.9
DELIVERY OF BORON-CONTAINING MACROMOLECULES TO BRAIN TUMORS 142 4.9.1
GENERAL CONSIDERATIONS 142 4.9.2 DRUG-TRANSPORT VECTORS 242 4.9.3 DIRECT
INTRACEREBRAL DELIVERY 142
4.9.4 CONVECTION-ENHANCED DELIVERY (CED) 143 4.10 CLINICAL
CONSIDERATIONS AND CONCLUSIONS 144 ACKNOWLEDGMENTS 145 REFERENCES 145
5 LOCAL CANCER THERAPY WITH MAGNETIC DRUG TARGETING USING MAGNETIC
NANOPARTICLES 156 CHRISTOPH ALEXIOU AND ROLAND JURGONS 5.1 INTRODUCTION
256
5.2 LOCAL CHEMOTHERAPY 156 5.3 MAGNETIC DRUG DELIVERY 158 5.3.1 IN VITRO
APPLICATIONS 158 5.3.2 IN VIVO APPLICATIONS 159
REFERENCES 163
6 NANOMATERIALS FOR CONTROLLED RELEASE OF ANTICANCER AGENTS 168 DO KYUNG
KIM, YUN SUKJO, JON DOBSON, ALICIA EL HAJ, AND MAMOUN MUHAMMED 6.1
INTRODUCTION 168
6.2 NANOPARTICLES FOR BIOMEDICAL APPLICATIONS 270 6.2.1 FIRST GENERATION
NANOPARTICLES 171 6.2.2 SECOND GENERATION NANOPARTICLES 171 6.2.3
ADVANCED GENERATION NANOPARTICLES 272 6.3 POLYMER MATERIALS FOR DRUG
DELIVERY SYSTEMS 274 6.4 DESIGN OF DRUG DELIVERY VECTORS AND THEIR
PREREQUISITES 275
6.4.1 POLYMERIC NANOPARTICLES 175 6.4.2 INORGANIC NANOPARTICLES 180
6.4.3 METALLIC NANOPARTICLES 182 6.5 KINETICS OF THE CONTROLLED RELEASE
OF ANTICANCER AGENTS 281
6.5.1 DIFFUSION MODEL 182 6.5.2 DISSOLUTION MODEL 283 6.5.3 KINETICS OF
THE INDOMETHACIN (IMC, L-[P-CHLOROBENZOYL]-2-METHYL-5-
METHOXY-3-INDOLEACETIC ACID) RELEASE 183
6.6 CONTROLLED RELEASE OF ANTICANCER AGENTS 286
IMAGE 5
CONTENTS IX
6.6.1 ALKYLATING AGENTS 186
6.6.1.1 CHLORAMBUCIL 187 6.6.1.2 CYDOPHOSPHAMIDE 187 6.6.1.3 CARMUSTINE
188 6.6.2 ANTIMETABOLIC AGENT 288 6.6.2.1 CYTARABINE 188
6.6.2.2 FLUOROURACIL (FU) 189 6.6.2.3 METHOTREXATE 189 6.6.3 ANTICANCER
ANTIBIOTICS 290
6.6.3.1 ACTINOMYCIN D 290 6.6.3.2 BLEOMYCIN 290 6.6.3.3 DAUNORUBICIN 191
6.7 FUTURE DIRECTIONS 191
REFERENCES 192
7 CRITICAL ANALYSIS OF CANCER THERAPY USING NANOMATERIALS 299 LUCIENNE
JUILLERAT-JEANNERET
7.1 INTRODUCTION 299
7.2 ANTICANCER THERAPIES 200 7.3 CHARACTERISTICS OF NANOPARTICLES FOR
CANCER THERAPY 202 7.3.1 NANOVECTORS 203 7.3.2 BIOLOGICAL ISSUES 205
7.3.3 NANOPARTICLE TARGETING: PASSIVE OR ACTIVE 206 7.4 NANOVECTORS IN
BIOMEDICAL APPLICATIONS: DRUG DELIVERY SYSTEMS (DDS)
FOR CANCER 207
7.4.1 PHYSICOCHEMICAL DRUG DELIVERY 208 7.4.2 BIOLOGICAL DRUG DELIVERY
208 7A3 CHEMICAL DRUG DELIVERY 208 7.4.4 NANOPARTICLES FOR ANTICANCER
DRUG DELIVERY 209 7 A A.I EXISTING SYSTEMS 209 7.4.4.2 SYSTEMS UNDER
DEVELOPMENT AND CHALLENGES 210 7.4.5 NANOPARTICLES FOR DRUG DELIVERY IN
CLINICAL USE OR UNDER CLINICAL
EVALUATION 222
7.4.5.1 DOXORUBICIN FAMILY 211 7.4.5.2 PACLITAXEL (TAXOL) 222 7.4.5.3
5-FLUOROURACIL 213 7.4.5.4 TAMOXIFEN 213 7.4.5.5 CISPLATIN 223 7.4.5.6
CAMPTHOTECINS 214 7.4.5.7 METHOTREXATE 214 7.4.6 NEW EXPERIMENTAL DRUGS
AND THERAPIES 224 7.4.6.1 PROTEINS, PEPTIDES, THEIR INHIBITORS AND
ANTAGONISTS 214 7.4.6.2 NEW DRUGS 225 7.4.6.3 NEW THERAPEUTIC
APPROACHES: PHOTODYNAMIC THERAPY (PDT) 225
IMAGE 6
X CONTENTS
7.4.7 GENE THERAPY 225
7.4.7.1 NANOPARTICLE FOR GENE DELIVERY: NON-CHITOSAN AND CHITOSAN-TYPE
POLYMERS 226 7.4.8 NEW APPROACHES 226 7.4.8.1 IMPROVEMENT OF BIOLOGICAL
CHARACTERISTICS 227 7.4.8.2 NEW TECHNOLOGICAL APPROACHES 219 7.4.9
SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLES (SPIONS) AS MAGNETIC
DRUG NANOVECTORS 219 7.5 TARGETING 220
7.5.1 PASSIVE TARGETING 222 7.5.2 ACTIVE TARGETING 223 7.5.2.1 TARGETING
CANCER-ASSOCIATED CELLS 223 7.5.2.2 TARGETING CANCER MARKERS 224 7.5.3
INTRACELLULAR DRUG DELIVERY 225 7.5.4 DEVELOPMENT OF THE NECESSARY
CHEMISTRY: SYNTHETIC ROUTES
AND LINKERS FOR CONJUGATION 226 7.6 OVERCOMING THE MECHANISMS OF
RESISTANCE TO THERAPY OF CANCERS 227 7.7 TOXICITY ISSUES 229
7.8 CONCLUSIONS 231
7.8.1 OPPORTUNITIES AND CHALLENGES OF NANOMEDICINE IN CANCER 231
REFERENCES 232
8 NANOPARTICLES FOR THERMOTHERAPY 242
ANDREAS JORDAN, KLAUS MAIER-HAUFF, PETER WUST, AND MANFRED JOHANNSEN
8.1 INTRODUCTION 242
8.2 THERMOTHERAPY FOLLOWING INTRATUMORAL ADMINISTRATION OF MAGNETIC
NANOPARTICLES 244 8.3 FERROMAGNETIC EMBOLIZATION HYPERTHERMIA 248 8.4
FIRST CLINICAL EXPERIENCES WITH THERMOTHERAPY USING MAGNETIC
NANOPARTICLES: MAGFORCE NANOTHERAPY 249 8.4.1 FEASIBILITY STUDY ON
THERMOTHERAPY USING MAGNETIC NANOPARTICLES IN RECURRENT GLIOBLASTOMA
MULTIFORME 250 8.4.2 FEASIBILITY STUDY ON THERMOTHERAPY USING MAGNETIC
NANOPARTICLES IN
RECURRENT AND RESIDUAL TUMORS 251 8.4.3 FEASIBILITY STUDY ON
THERMOTHERAPY USING MAGNETIC NANOPARTICLES IN RECURRENT PROSTATE
CARCINOMA 253 REFERENCES 254
9 FERROMAGNETIC FILLED CARBON NANOTUBES AS NOVEL AND POTENTIAL
CONTAINERS FOR ANTICANCER TREATMENT STRATEGIES 259
INGOLF MOENCH, AXEL MEYE, AND ALBRECHT LEONHARDT
9.1 INTRODUCTION 259
9.2 PROSTATE CANCER 260
9.2.1 INCIDENCE, RISK FACTORS AND DIAGNOSTIC CRITERIA 260 9.2.2
TREATMENT OPTIONS, OUTCOME AND LIMITS 261
IMAGE 7
CONTENTS I XI
9.2.3 MWCNT MODEL 263
9.3 CARBON NANOTUBES 264
9.3.1 GENERAL REMARKS 264 9.3.2 PREPARATION AND STRUCTURE OF FILLED
MULTI-WALLED CARBON NANOTUBES 266 9.3.2.1 SYNTHESIS OF FERROMAGNETIC
FILLED MULTI-WALLED CARBON NANOTUBES 266 9.3.2.2 CRYSTALLOGRAPHIC
STRUCTURE OF CORE MATERIAL IN FILLED MULTI-WALLED
CARBON NANOTUBES 269 9.3.2.3 GROWTH MECHANISM OF MULTI-WALLED CARBON
NANOTUBES 271 9.3.3 POST-TREATMENT: OPENING, FILLING AND CLOSING OF
MWCNTS 275 9.4 MAGNETISM IN NANO-SIZED MATERIALS 277 9.4.1 GENERAL
REMARKS 277 9.4.2 MAGNETIZATION IN NANO-SIZED MATERIALS 278 9.4.3
INFLUENCE OF THE DIMENSIONS ON THE MAGNETIZATION DISTRIBUTION 279 9.4.4
ANISOTROPY AND INTERACTION 283 9.4.5 MAGNETIC REVERSAL 284 9.4.6
MAGNETIC PROPERTIES OF FILLED MULTI-WALLED CARBON NANOTUBES 285
9.5 HEAT GENERATION 290
9.5.1 GENERAL REMARKS 290 9.5.2 REQUIREMENTS FOR THE DEVELOPMENT OF
MATERIALS FOR HYPERTHERMIA AND MAGNETISM 296
9.5.3 SPECIFIC ABSORPTION RATE (SAR) 300 9.6 STUDY RESULTS FOR IN VITRO
AND IN VIVO APPLICATIONS OF FF-MWCNTS 309 9.6.1 EFFICIENT ENDOCYTOSIS IN
VITRO, LIPID-MEDIATED COULD ENHANCE THE INTERNALIZATION RATE AND
EFFICIENCY 309
9.6.2 PRODUCTION OF TWO TYPES OF FF-MWCNTS FOR IN VIVO APPLICATION 312
9.6.3 OUTLOOK/NEXT STEPS IN EVALUATION OF THESE FFF-MWCNTS 313
ACKNOWLEDGMENTS 324 ABBREVIATIONS 324
REFERENCES 325
10 LIPOSOMES, DENDRIMERS AND OTHER POLYMERIC NANOPARTICLES FOR TARGETED
DELIVERY OF ANTICANCER AGENTS - A COMPARATIVE STUDY 338
YONG ZHANG AND DEV K. CHATTERJEE
10.1 INTRODUCTION 338
10.2 CANCER CHEMOTHERAPY: SO FAR, BUT NOT SO GOOD 339 10.3 NANOPARTICLES
AND DRUG DELIVERY IN CANEEN A NEW ROAD 341 10.3.1 IMPORTANCE OF
NANOPARTICLES IN CANCER THERAPY 341 10.3.2 AN OVERVIEW OF TARGETING
METHODS 343
10.4 MEANS TO THE END: METHODS FOR TARGETING 343 10.4.1 PASSIVE
TARGETING 343 10.4.2 MAGNETIC TARGETING OF NANOPARTICLES 345 10.4.3
IIGANDS FOR ACTIVE TARGETING 346 10.4.3.1 MONOCLONAL ANTIBODIES AGAINST
TUMOR-SPECIFIC ANTIGENS 347 10.4.3.2 TARGETING THE ANGIOGENIC PROCESS
349
IMAGE 8
XII CONTENTS
10.4.3.3 FOLIE ACID AND CANCER TARGETING 350
10.4.3.4 TRANSFERRIN AS A TARGETING LIGAND 354 10.4.3.5 OTHER TARGETING
LIGANDS 354 10.5 TARGETING WITH DIFFERENT TYPES OF NANOPARTICLES 355
10.5.1 LIPOSOMES IN CANCER TARGETING 355 10.5.1.1 BEYOND IMMUNOLIPOSOMES
357 10.5.2 DENDRIMERS 357 10.5.3 OTHER POLYMERIC NANOPARTICLES 359 10.6
CONCLUSION 362
REFERENCES 364
11 COLLOIDAL SYSTEMS FOR THE DELIVERY OF ANTICANCER AGENTS IN BREAST
CANCER AND MULTIPLE MYELOMA 371
SEBASTIEN MAILLARD, ELIAS FATTAL, VERONIQUE MARSAUD, BRIGITTE SOLA, AND
JACK-MICHEL RENOIR
11.1 INTRODUCTION 372
11.2 HORMONE THERAPY IN BREAST CANCERS 374 11.2.1 MOLECULAR MECHANISMS
OF ESTROGEN ACTION IN BREAST CANCERS 375 11.2.1.1 CLASSICAL ER-LIGAND
AND ERE-DEPENDENT MECHANISM 375 11.2.1.2 ERE-INDEPENDENT PATHWAY 377
11.2.1.3 ER-LIGAND-INDEPENDENT PATHWAY 377 11.2.1.4 "NON-GENOMIC"
PATHWAY 378 11.2.2 DIFFERENTIAL ACTIVITY OF ANTIESTROGENS 378 11.2.3 THE
NEED TO ENCAPSULATE ANTIESTROGENS 379
11.3 MULTIPLE MYELOMA 380 11.3.1 CURRENT TREATMENTS 380 11.3.2 NEW
BIOLOGICAL THERAPIES FOR MM TREATMENT 380 11.3.3 INCIDENCE OF ESTROGENS
AND ANTIESTROGENS ON MULTIPLE MYELOMA 381 11.4 COLLOIDAL SYSTEMS FOR
ANTIESTROGEN DELIVERY 382 11.4.1 NANOPARTICLES CHARGED WITH AES IN
BREAST CANCER 382
11.4.2 LIPOSOMES CHARGED WITH RU 58668 IN MM 386 11.4.3 TUMOR-TARGETED
DRUG-LOADED COLLOIDAL SYSTEMS 387 11.5 CONCLUSIONS AND PERSPECTIVES 390
ACKNOWLEDGMENTS 391
REFERENCES 391
INDEX 404 |
| any_adam_object | 1 |
| author2 | Kumar, Challa S. S. R. |
| author2_role | edt |
| author2_variant | c s s r k cssr cssrk |
| author_GND | (DE-588)129740470 |
| author_facet | Kumar, Challa S. S. R. |
| building | Verbundindex |
| bvnumber | BV039691964 |
| ctrlnum | (OCoLC)918160013 (DE-599)DNB1014987741 |
| discipline | Maschinenbau / Maschinenwesen Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>00000nam a2200000 cc4500</leader><controlfield tag="001">BV039691964</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20230825</controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">111109s2011 gw ad|| |||| 00||| eng d</controlfield><datafield tag="015" ind1=" " ind2=" "><subfield code="a">11,A38</subfield><subfield code="2">dnb</subfield></datafield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">1014987741</subfield><subfield code="2">DE-101</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783527331369</subfield><subfield code="9">978-3-527-33136-9</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)918160013</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DNB1014987741</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakddb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">gw</subfield><subfield code="c">XA-DE-BW</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-634</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">620</subfield><subfield code="2">sdnb</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">610</subfield><subfield code="2">sdnb</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Nanotechnology of the life sciences</subfield><subfield code="n">6</subfield><subfield code="p">Nanomaterials for cancer therapy</subfield><subfield code="c">ed. by Challa S. S. R. Kumar</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Weinheim</subfield><subfield code="b">Wiley-VCH-Verl.</subfield><subfield code="c">2011</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XIX, 413 S.</subfield><subfield code="b">Ill., graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kumar, Challa S. S. R.</subfield><subfield code="0">(DE-588)129740470</subfield><subfield code="4">edt</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="w">(DE-604)BV039691867</subfield><subfield code="g">6</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">DNB Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=024540714&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-024540714</subfield></datafield></record></collection> |
| id | DE-604.BV039691964 |
| illustrated | Illustrated |
| indexdate | 2024-07-21T00:15:23Z |
| institution | BVB |
| isbn | 9783527331369 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-024540714 |
| oclc_num | 918160013 |
| open_access_boolean | |
| owner | DE-634 |
| owner_facet | DE-634 |
| physical | XIX, 413 S. Ill., graph. Darst. |
| publishDate | 2011 |
| publishDateSearch | 2011 |
| publishDateSort | 2011 |
| publisher | Wiley-VCH-Verl. |
| record_format | marc |
| spelling | Nanotechnology of the life sciences 6 Nanomaterials for cancer therapy ed. by Challa S. S. R. Kumar Weinheim Wiley-VCH-Verl. 2011 XIX, 413 S. Ill., graph. Darst. txt rdacontent n rdamedia nc rdacarrier Kumar, Challa S. S. R. (DE-588)129740470 edt (DE-604)BV039691867 6 DNB Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=024540714&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Nanotechnology of the life sciences |
| title | Nanotechnology of the life sciences |
| title_auth | Nanotechnology of the life sciences |
| title_exact_search | Nanotechnology of the life sciences |
| title_full | Nanotechnology of the life sciences 6 Nanomaterials for cancer therapy ed. by Challa S. S. R. Kumar |
| title_fullStr | Nanotechnology of the life sciences 6 Nanomaterials for cancer therapy ed. by Challa S. S. R. Kumar |
| title_full_unstemmed | Nanotechnology of the life sciences 6 Nanomaterials for cancer therapy ed. by Challa S. S. R. Kumar |
| title_short | Nanotechnology of the life sciences |
| title_sort | nanotechnology of the life sciences nanomaterials for cancer therapy |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=024540714&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| volume_link | (DE-604)BV039691867 |
| work_keys_str_mv | AT kumarchallassr nanotechnologyofthelifesciences6 |